The levels of service within an evaluation and management (E/M) visit are based on the documentation of key components, which include history, physical examination and medical decision making. The history component is comparable to telling a story and should include a beginning and some form of development to adequately describe the patient’s presenting problem. To…
The ACR Gears Up for Rheumatic Disease Awareness Month in September
Awareness can be an ambiguous term, but it makes all the difference in rheumatology. The first weeks and months following the onset of rheumatic disease symptoms are known as the window of opportunity. Prompt treatment can prevent damage to joints and other organs, improve long-term function and increase the likelihood of achieving disease remission. But…
Rheumatology Research Foundation Grants 63 Education, Training, Research Awards
On July 3, the Rheumatology Research Foundation announced the names of 63 rheumatology trainees, educators, clinicians, investigators and health professionals who will receive Foundation-funded awards. In support of the Foundation’s mission to improve the health of people with rheumatic diseases, the awards help recruit and train the next generation of rheumatology professionals and advance research…
The ACR Board of Directors Adopts 5-Year Strategic Plan
Rheumatology is at a critical juncture in our history. To advance into the future, the ACR must thoroughly prepare for changing political landscapes, emerging technologies and workforce challenges. On May 12, the ACR Board of Directors met in Washington, D.C., to approve our ambitious new Strategic Plan for 2017–2022. This plan encompasses five strategic themes…
How Global Geographic Disparities Affect Healthcare Outcomes
Your home & your health: Does geography impact medicine? Does it matter whether a region is surrounded by large bodies of water, encircled by towering mountain peaks or that its residents share a common ancestry? Consider Switzerland, a nation with a highly developed economy replete with advanced technological and medical infrastructure. Despite these advantages, less…
Mallinckrodt Settles U.S. Opioid Drug Probe for $35 million
(Reuters)—Mallinckrodt Plc., one of the largest manufacturers of the generic opioid painkiller oxycodone, will pay $35 million to resolve allegations that it failed to report suspicious drug orders, the U.S. Justice Department said on Tuesday. The deal, in which Mallinckrodt did not admit wrongdoing, marked a record settlement of claims that a drugmaker failed to properly…
CVS to Pay $5 Million to Resolve U.S. Drug Probe
(Reuters)—CVS Health Corp. has paid $5 million to resolve allegations that pharmacies it operates in California failed to keep and maintain accurate records of prescription drugs, the U.S. Justice Department said on Tuesday. The deal follows an investigation that began in 2012 after the U.S. Drug Enforcement Administration noticed an increased number of thefts and unexplained…
Senate May Vote on Revised Healthcare Bill Next Week
WASHINGTON (Reuters)—U.S. Senate Republicans said Tuesday they will seek to bring their healthcare overhaul to the Senate floor next week after a lengthy intraparty struggle, but it remained unclear whether they had the votes to pass the measure or even what form it would finally take. With his reputation as a master strategist on the…
A Stiff Man: A Case Study in Ankylosing Spondylitis
First Appearances I watched the old man, his back painfully bent, shuffle toward the scale. A blocky rigidity draped over him. His feet seemed stuck to the floor. His head hung heavily over his chest. Observing him from the end of the hallway, instead of a face, I saw only a mound of shaggy, matted…
Opana ER Pulled from U.S. Market
Endo Pharmaceuticals will work with the FDA to coordinate the organized removal of Opana ER from the U.S. market.
- « Previous Page
- 1
- …
- 377
- 378
- 379
- 380
- 381
- …
- 778
- Next Page »